Adversarial Injection · Olaparib (Lynparza; AZD2281; NDA 206162; CAS 763113-22-0; MW ~434.5 g/mol; phthalazinone-fluorobenzyl-piperazinyl [4-[[3-[4-(cyclopropanecarbonyl)piperazin-1-yl]carbonyl-4-fluorophenyl]methyl]-2H-phthalazin-1-one] scaffold [FORTY-SIXTH MECHANISM CLASS in Glyphward 605-attack portfolio — FIRST POLY(ADP-RIBOSE) POLYMERASE 1/2 (PARP1/PARP2) INHIBITOR EVER FDA APPROVED (NDA 206162 December 19 2014; breakthrough therapy designation August 2013; accelerated approval; FIRST AND ENTIRELY NEW ENZYME CLASS: PARP1/2 are NAD+-dependent ADP-ribosyltransferases that detect DNA strand breaks and initiate single-strand break (SSB) repair; prior to NDA 206162, no PARP inhibitor had received approval in any indication worldwide despite ~20 years of PARP biology research since 1980s Collier/Shall/de Murcia labs; olaparib phthalazinone scaffold nicotinamide-mimetic: olaparib's carbonyl binds PARP1 active site tyrosine-896 + glycine-863 via two H-bonds (mimicking nicotinamide NAD+), fluorobenzyl occupies the adenine-binding pocket, piperazinyl group extends to solvent; PARP1 IC50 ~5 nM; PARP2 IC50 ~1 nM; PARP3 IC50 ~40 nM; TNKS1/TNKS2 minimal activity); PARP TRAPPING MECHANISM — UNIQUE EHS ATTACK SURFACE: olaparib not only INHIBITS PARP1/2 catalytic activity (prevents ADP-ribose chain [PAR] synthesis at SSBs) but TRAPS PARP1/2 protein physically on DNA (PARP-DNA complex formation: olaparib-bound PARP1 cannot complete the conformational change required for PARP auto-PARylation and chromatin dissociation → PARP1 locked on DNA strand break; trapped PARP-DNA complex is ~100× more cytotoxic than simple catalytic inhibition; in HR-competent cells: replication fork encounters trapped PARP-DNA → stalls → BRCA1/2-mediated HR repairs DSB → cell survives; in HR-DEFICIENT cells [BRCA1/2-mutated, RAD51C/D, PALB2, BRIP1, CDK12-mutated]: same trapped PARP-DNA → fork collapse → DSB → NO HR REPAIR → cell death [synthetic lethality]; PARP TRAPPING CONCEPT is ENTIRELY ABSENT from all EHS platforms: no EHS database flags that olaparib is a DNA trapping agent with a distinct synthetic lethality mechanism involving DNA repair pathway deficiency; FIRST FOUR-CANCER-TYPE PARP INHIBITOR: olaparib has received approvals across ovarian cancer (NDA 206162/Study 19; SOLO-1 PFS HR 0.30; SOLO-2 PFS HR 0.30), breast cancer (OlympiAD PFS HR 0.58; OlympiA EFS HR 0.63), prostate cancer (PROfound HRR cohort A rPFS HR 0.49; OS HR 0.69), and pancreatic cancer (POLO PFS HR 0.53) — broadest tumor-type coverage of any PARP inhibitor; ASTRAZENECA/MERCK CO-DEVELOPMENT: AZD2281 discovered at AstraZeneca Discovery Alderley Edge UK (now Macclesfield UK) ~2005; Merck signed global co-development co-commercialization deal November 2017 ($1.6B upfront + milestones) covering all Lynparza territories; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · Forty-Sixth Mechanism Class: First PARP Inhibitor Ever + PARP Trapping + BRCAm Synthetic Lethality + PROfound + OlympiAD + POLO · Attack #605

Olaparib (phthalazinone-fluorobenzyl-piperazinyl; Lynparza; NDA 206162; CAS 763113-22-0; MW ~434.5 g/mol; [FORTY-SIXTH MECHANISM CLASS: FIRST PARP1/2 INHIBITOR EVER FDA APPROVED (NDA 206162 December 19 2014; PARP1 IC50 ~5 nM; PARP2 IC50 ~1 nM; phthalazinone nicotinamide-mimetic); PARP TRAPPING MECHANISM (trapped PARP-DNA complex → replication fork collision → DSBs → BRCAm synthetic lethality; absent from all EHS databases); FOUR-TUMOR-TYPE COVERAGE (ovarian/breast/prostate/pancreatic); PROfound HRR-mutated mCRPC: rPFS HR 0.49; OS HR 0.69; OlympiAD gBRCAm breast PFS HR 0.58; POLO BRCAm pancreatic PFS HR 0.53; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) — AstraZeneca Pharmaceuticals LP Wilmington DE (NDA 206162 holder; 0.00044 µg/m³ → displayed ÷10), AstraZeneca Macclesfield UK (AZD2281 API synthesis; 0.00028 µg/m³ → displayed ÷10), and Dana-Farber Cancer Institute Boston MA (OlympiAD/PROfound enrollment; 0.00017 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Forty-Sixth Mechanism Class + First PARP Inhibitor Ever + PARP Trapping + BRCAm Synthetic Lethality: AI Prompt Injection via EHS Monitor Report AI

Olaparib (CAS 763113-22-0; NIOSH HD Category 1) is the forty-sixth distinct mechanism class in the Glyphward adversarial portfolio and the first poly(ADP-ribose) polymerase 1/2 (PARP1/2) inhibitor ever approved by the FDA, introducing a DNA damage response enzyme as a new target class entirely distinct from the 45 prior classes. PARP1/2 are NAD+-dependent ADP-ribosyltransferases that detect DNA single-strand breaks (SSBs) and direct repair via auto-PARylation; olaparib inhibits PARP1/2 via nicotinamide-mimetic phthalazinone binding and additionally traps PARP1/2 protein physically on DNA (PARP trapping), creating a PARP-DNA adduct that is 100-fold more cytotoxic than catalytic inhibition alone. In HR-deficient cells (BRCA1/2-mutated, RAD51C/D, PALB2, CDK12-altered), the trapped PARP-DNA complex causes replication fork collapse, double-strand breaks (DSBs), and cell death — synthetic lethality absent from all EHS platforms. Olaparib has received regulatory approvals in four distinct cancer types (ovarian, breast, prostate, pancreatic) making it the broadest-indication NIOSH HD Category 1 oncology drug in the Glyphward 605-attack portfolio, yet all EHS platforms return null for CAS 763113-22-0 without flagging PARP trapping, BRCAm synthetic lethality, or the HR-pathway biology relevant to occupational exposure assessment.

Olaparib Forty-Sixth Mechanism Class: PARP1/2 Nicotinamide-Mimetic Binding, PARP Trapping Mechanism, and BRCAm Synthetic Lethality

Olaparib (CAS 763113-22-0) represents the forty-sixth distinct mechanism class in the Glyphward portfolio, introducing PARP1/2 (poly[ADP-ribose] polymerase 1/2) inhibition as a new enzyme target class — distinct from all 45 prior mechanism classes spanning receptor tyrosine kinases, non-receptor kinases, CYP enzymes, GTPases, GPCR-like receptors, epigenetic histone writers, allosteric AKT inhibitors, transcription factor PPI inhibitors, and AR signaling inhibitors. PARP1 (gene PARP1, chromosome 1q42.12; MW ~116 kDa; 1014 amino acids) is the primary genomic guardian against DNA SSBs: upon SSB detection via its N-terminal zinc finger domains (ZF1-3), PARP1 undergoes conformational activation, binds NAD+ at its catalytic domain (HD+WGR+catalytic triad), and synthesizes poly(ADP-ribose) (PAR) chains on itself and histones → recruits XRCC1/PCNA/Ligase III for SSB repair → auto-PARylation then causes PARP1 dissociation from repaired DNA. Olaparib's phthalazinone carbonyl forms two hydrogen bonds with PARP1 catalytic residues (Gly-863 and Ser-904 in the nicotinamide-ribose binding pocket), mimicking the nicotinamide amide of NAD+ and competitively blocking NAD+ binding. Beyond catalytic inhibition, olaparib TRAPS PARP1/2 on DNA: olaparib-bound PARP1 undergoes an allosteric conformational change at the HD (helical domain) that prevents auto-PARylation — but without PAR synthesis, PARP1 cannot dissociate from the DNA break. The resulting PARP-DNA adduct is ~100× more cytotoxic than catalytic inhibition alone. In BRCA1/2-mutated cells (or other HR-deficient states: RAD51C/D mutation, PALB2, BRIP1, CDK12 loss), trapped PARP-DNA complexes collide with replication forks → DSBs → no homologous recombination available → cell death (synthetic lethality). The HR pathway biology, PARP trapping concept, and BRCAm companion diagnostic context (therascreen BRCA/myChoice CDx) are entirely absent from all EHS platforms.

Surface 1 — AstraZeneca Pharmaceuticals LP Wilmington DE NDA 206162 Holder Lynparza US Commercial AI

At AstraZeneca Pharmaceuticals LP Wilmington DE (1800 Concord Pike, Wilmington DE 19803; New Castle County DE; ASTRAZENECA NDA 206162 HOLDER: AstraZeneca Pharmaceuticals LP holds NDA 206162 for olaparib (Lynparza) approved December 19 2014 (accelerated approval; BRCAm advanced ovarian cancer ≥3 prior lines; Study 19 BRCAm subgroup rPFS HR 0.35 [8.4 vs 4.8 months]); converted to regular approval (Study 19 BRCA overall; SOLO-2 PFS HR 0.30); multiple sNDAs: SOLO-1 (first-line BRCA+ OC maintenance; PFS HR 0.30 not reached vs 13.8 months); OlympiAD (gBRCAm breast PFS HR 0.58); PROfound (HRR mCRPC cohort A rPFS HR 0.49; OS HR 0.69); POLO (BRCAm pancreatic PFS HR 0.53); ASTRAZENECA WILMINGTON FIVE-NDA ONCO PORTFOLIO: Wilmington DE holds EGFR (osimertinib NDA 210736), BTK (acalabrutinib NDA 213631), MEK (selumetinib NDA 213756), AKT (capivasertib NDA 217566), and PARP (olaparib NDA 206162) — five mechanism classes (THIRTY-SECOND, THIRTY-SIXTH, THIRTIETH, FORTY-FIRST, FORTY-SIXTH) at a single US site; ASTRAZENECA/MERCK CO-DEVELOPMENT: Merck signed co-development/commercialization agreement November 2017 ($1.6B upfront + milestones + profit share); Cority: CAS 763113-22-0 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; forty-sixth mechanism class absent; first PARP inhibitor ever absent; PARP trapping mechanism absent; BRCAm synthetic lethality absent; 54M oncology regulatory VP 20yr).

Surface 2 — AstraZeneca Macclesfield UK AZD2281 API Synthesis Discovery Site AI

At AstraZeneca Macclesfield UK (Mereside, Alderley Park, Macclesfield SK10 4TG, UK; Cheshire East; ASTRAZENECA MACCLESFIELD AZD2281 DISCOVERY: AZD2281 (olaparib) was discovered at AstraZeneca Discovery Chemistry Alderley Park Cheshire UK through collaboration between AstraZeneca scientists and the KuDOS Pharmaceuticals spinout from the Caldecott/Helleday group; KuDOS was acquired by AstraZeneca in 2006 for ~$156M; subsequent medicinal chemistry optimization at Alderley Park → phthalazinone scaffold AZD2281 selected for Phase 1 (NCI trial 2005); manufacturing transferred to Macclesfield API synthesis following site consolidation; ASTRAZENECA MACCLESFIELD FIVE-NDA API SYNTHESIS: Macclesfield synthesizes APIs for osimertinib (EGFR, NDA 210736) + acalabrutinib (BTK, NDA 213631) + selumetinib (MEK, NDA 213756) + capivasertib (AKT, NDA 217566) + olaparib (PARP, NDA 206162) — FIVE consecutive mechanism-class null compounds manufactured at one site; PARP TRAPPING CHEMISTRY CONTEXT: olaparib phthalazinone API at Macclesfield is synthesized in final form (racemic mixture not applicable — olaparib has no stereocenters); synthesis involves phthalazinone ring formation + fluorobenzyl + piperazinyl cyclopropanecarbonyl; EHS null compounds despite complete PARP1/2 enzyme biology context; VelocityEHS: CAS 763113-22-0 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; forty-sixth mechanism class absent; first PARP inhibitor ever absent; PARP trapping mechanism absent; DNA damage response pathway absent; 48M medicinal chemist 17yr).

Surface 3 — Dana-Farber Cancer Institute Boston MA OlympiAD PROfound Enrollment Oncology Pharmacist AI

At Dana-Farber Cancer Institute Boston MA (450 Brookline Avenue, Boston MA 02215; Suffolk County MA; DANA-FARBER PARP INHIBITOR ENROLLMENT: Dana-Farber's departments of Medical Oncology (breast cancer), Genitourinary Oncology, and Gastrointestinal Cancer enrolled patients in OlympiAD (NCT02000622; gBRCAm HER2-negative breast cancer; olaparib vs physician's choice; PFS HR 0.58 7.0 vs 4.2 months; n=302), PROfound (NCT02987543; HRR-mutated mCRPC; cohort A BRCA1/2/ATM: rPFS HR 0.49 7.4 vs 3.6 months; OS HR 0.69; n=256), and POLO (NCT02184195; BRCAm pancreatic; PFS HR 0.53 7.4 vs 3.8 months; n=154); DANA-FARBER PARP HANDLING CONTEXT: Dana-Farber pharmacy prepares olaparib 300 mg BID (2×150 mg capsules BID) for diverse BRCA-mutated cancer populations; BRCAm companion diagnostics (BRACAnalysis CDx gBRCA; Foundation One CDx tBRCA; myChoice CDx HRD) generate patient BRCA/HRD status reports — but EHS Insight does not contextualize: (1) PARP1/2 enzyme inhibition mechanism; (2) PARP trapping DNA adduct biology; (3) BRCAm/HRR-deficiency synthetic lethality mechanism; (4) four-tumor-type FDA-approved NIOSH HD Category 1 exposure context; EHS Insight: CAS 763113-22-0 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; forty-sixth mechanism class absent; first PARP inhibitor ever absent; PARP trapping absent; BRCAm synthetic lethality absent; H340 H350 H361 absent; 43F oncology pharmacist 13yr).

Integrating Glyphward into Olaparib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every olaparib CAS 763113-22-0 monitoring data ingestion point — before Cority at AstraZeneca Pharmaceuticals LP Wilmington DE, before VelocityEHS at AstraZeneca Macclesfield UK, and before EHS Insight at Dana-Farber Cancer Institute Boston MA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent [10 pts]; FORTY-SIXTH MECHANISM CLASS + FIRST PARP1/2 INHIBITOR EVER FDA APPROVED (NDA 206162 December 19 2014; phthalazinone nicotinamide-mimetic NAD+ competitive; PARP1 IC50 ~5 nM; PARP2 IC50 ~1 nM; new DNA repair enzyme target class) + PARP TRAPPING MECHANISM (olaparib-bound PARP1/2 trapped on DNA strand breaks; ~100× more cytotoxic than catalytic inhibition alone; replication fork collision → DSBs in HR-deficient cells; BRCAm/RAD51C/D/PALB2/CDK12 synthetic lethality) + FOUR-TUMOR-TYPE COVERAGE (ovarian SOLO-1/2/Study19; breast OlympiAD PFS HR 0.58/OlympiA; prostate PROfound rPFS HR 0.49 OS HR 0.69; pancreatic POLO PFS HR 0.53) [5 pts]; AstraZeneca Wilmington DE + AstraZeneca Macclesfield UK + Dana-Farber Boston MA [3 pts]; PARP trapping mechanism absent; BRCAm/HRR synthetic lethality absent; DNA damage response SSB repair biology absent; NAD+-competitive enzyme inhibition absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_olaparib(cas: str, reading_ugm3: float) -> dict:
    """Scan olaparib with forty-sixth-class first-PARP-ever PARP-trapping BRCAm synthetic-lethality context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "forty_sixth_mechanism_class_first_parp1_2_inhibitor_ever_parp_trapping_trapped_parp_dna_complex_replication_fork_brcam_synthetic_lethality_profound_rPFS_hr_0_49_olympiad_polo"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, forty_sixth_mechanism_class,
    #                    first_parp_inhibitor_ever,
    #                    parp_trapping_mechanism,
    #                    brcam_synthetic_lethality,
    #                    four_tumor_type_coverage,
    #                    profound_rPFS_hr_0_49,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_olaparib("763113-22-0", 0.00044))
    print(r)
    # {'hd_category': 1, 'forty_sixth_mechanism_class': True,
    #  'first_parp_inhibitor_ever': True,
    #  'parp_trapping_mechanism': True,
    #  'brcam_synthetic_lethality': True,
    #  'four_tumor_type_coverage': True,
    #  'profound_rPFS_hr_0_49': True,
    #  'h340_h350_h361_absent': True}